SCHEMBL1703586

SCHEMBL1703586

Cn1cc(Nc2ncc(Cl)c(Nc3ccccc3CO)n2)cn1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALK Q9UM73 6/20 0.69
▸ CDK19 Q9BWU1 4/20 0.69
▸ JAK2 O60674 6/20 0.68
▸ CDC7 O00311 2/20 0.68
▸ DAPK3 O43293 2/20 0.68
▸ ROCK2 O75116 2/20 0.68
▸ PRKD3 O94806 2/20 0.68
▸ MAP4K4 O95819 2/20 0.68
▸ PAK4 O96013 2/20 0.68
▸ PIM1 P11309 2/20 0.68
▸ PRKACA P17612 2/20 0.68
▸ CDK2 P24941 2/20 0.68
▸ SYK P43405 2/20 0.68
▸ CSNK1A1 P48729 2/20 0.68
▸ CLK2 P49760 2/20 0.68
▸ GSK3A P49840 2/20 0.68
▸ GSK3B P49841 2/20 0.68
▸ CDK7 P50613 2/20 0.68
▸ CDK9 P50750 2/20 0.68
▸ PRKX P51817 2/20 0.68

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1703321 0.82 ALK (0.67) ALKCDK19JAK2CDC7DAPK3
SCHEMBL2127160 0.81 JAK2 (0.65) ALKCDK19JAK2CDC7DAPK3
SCHEMBL2123417 0.80 ALK (0.67) ALKCDK19JAK2CDC7DAPK3
SCHEMBL1703311 0.80 JAK2 (0.64) ALKCDK19JAK2CDC7DAPK3
SCHEMBL14662261 0.78 CDK19 (0.67) ALKCDK19JAK2CDC7DAPK3
SCHEMBL14670406 0.78 CDK19 (0.67) ALKCDK19JAK2CDC7DAPK3
SCHEMBL14662070 0.78 CDK19 (0.67) ALKCDK19JAK2CDC7DAPK3
SCHEMBL15547660 0.78 CDK19 (0.64) ALKCDK19JAK2CDC7DAPK3
SCHEMBL25559576 0.78 MAPK8 (0.69) ALKCDK2CDK9STK17AMAP3K7
SCHEMBL1703985 0.77 CDK9 (0.61) ALKCDK19JAK2CDC7DAPK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2440548-A1 2- ( LH-PYRAZOL-4 -YLAMINO ) -PYRIMIDINE AS KINASE INHIBITORS Abbott Laboratories (US) 2012-04-18 — — EP claimed
US-20100317680-A1 PYRIMIDINE INHIBITORS OF KINASES ABBOTT LABORATORIES (US) 2010-12-16 — — US claimed
WO-2010144468-A1 2- ( LH-PYRAZOL-4 -YLAMINO ) -PYRIMIDINE AS KINASE INHIBITORS ABBOTT LABORATORIES (US) 2010-12-16 — — WO claimed
US-8426408-B2 Pyrimidine inhibitors of kinases ABBVIE INC. (US) 2013-04-23 — — US disclosed
EP-2440548-A1 2- ( LH-PYRAZOL-4 -YLAMINO ) -PYRIMIDINE AS KINASE INHIBITORS Abbott Laboratories (US) 2012-04-18 — — EP disclosed
US-20100317680-A1 PYRIMIDINE INHIBITORS OF KINASES ABBOTT LABORATORIES (US) 2010-12-16 — — US disclosed
WO-2010144468-A1 2- ( LH-PYRAZOL-4 -YLAMINO ) -PYRIMIDINE AS KINASE INHIBITORS ABBOTT LABORATORIES (US) 2010-12-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100317680-A1 PYRIMIDINE INHIBITORS OF KINASES AURKA, AURKC, AURKB ALK 324/4885CDK19 57/4885JAK2 256/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback